StockTipsArenaBeta

BUY Dr. Lal Path Labs Ltd. — Kush Bohra

BUYDr. Lal Path Labs Ltd.
Dr. Lal Path Labs share price target & all analyst calls

byKush BohraHorizon: NA (inferred Swing (≤2wk))3 Aug 2026via NDTV Profit

Entry₹1,920Inferred
Target₹2,090
Total upside +8.85% (call closed)
Stop loss₹1,825-4.95% risk
At expiry₹1,917.314 Aug 2026, 3:30 pm
Expired-0.14%
Follow Kush Bohra for new calls(32% target hit, 190 closed calls)Get alertsWatch LALPATHLAB for new buy/sell callsGet alertsSee 149 active Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 14 Aug 2026
10 supporting1 neutral0 opposing
Supports the BUY call (10)

1 other SEBI-registered advisor has an active swing BUY call on this stock, issued in the last 14 days

Advisor consensus · same horizon·11 Aug · 3d ago

Metropolis Healthcare: చిన్న పట్టణాల్లో దూసుకుపోతోంది.. లాభాల్లో **26%** వృద్ధి!

NewsGoogle News·6 Aug · 1w ago

(opens in new tab)

Metropolis Healthcare शेअरमध्ये तेजी! टियर-II/III शहरांमधील विस्ताराने नफा **26%** ने वाढला

NewsGoogle News·6 Aug · 1w ago

(opens in new tab)

2 advisors have active short-term BUY calls on this stock

Advisor consensus · adjacent horizon·30 Jul · 2w ago

Dr Lal Path Labs shares soar 8% after Q1 earnings beat estimates. What Nomura, Nuvama, other brokerages are saying?

NewsEt-Markets·27 Jul · 3w ago

(opens in new tab)
Neutral / worth noting (1)

The Board of Directors approved un-audited financial results for Q1 FY27, declared an interim dividend of INR 5 per share, and approved the grant of stock options. Additionally, the company approved a

BSE · Company Update·24 Jul · 3w ago

(opens in new tab)
Weighs against the BUY call (0)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Dr. Lal Path Labs

All analyst calls on Dr. Lal Path Labs

More from Kush Bohra

Every call and its outcome